Genmab A/S (NASDAQ:GMAB) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 3,049.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 407,613 shares of the company's stock after purchasing an additional 394,670 shares during the period. JPMorgan Chase & Co. owned about 0.06% of Genmab A/S worth $8,507,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC increased its stake in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares during the last quarter. GAMMA Investing LLC lifted its position in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after buying an additional 1,051 shares during the period. Cromwell Holdings LLC boosted its stake in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares during the last quarter. Finally, R Squared Ltd acquired a new position in shares of Genmab A/S during the 4th quarter valued at about $93,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Up 2.5 %

Shares of NASDAQ GMAB traded up $0.49 on Friday, hitting $20.04. The company had a trading volume of 1,135,288 shares, compared to its average volume of 1,038,357. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $30.41. The firm has a market capitalization of $13.26 billion, a P/E ratio of 11.52, a PEG ratio of 2.65 and a beta of 1.07. The business has a 50 day moving average of $20.54 and a two-hundred day moving average of $21.14.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Analyst Ratings Changes

GMAB has been the topic of several research analyst reports. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Truist Financial dropped their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and issued a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.